Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Intercept Pharmaceuticals Is Poised to Pull Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Intercept Pharmaceuticals (NASDAQ: ICPT  ) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Intercept and see what CAPS investors are saying about the stock right now.

Intercept facts

Headquarters (founded)

New York (2002)

Market Cap

$579.7 million



Trailing-12-Month Revenue

$2.4 million


Founder/CEO Mark Pruzanski
CFO Barbara Duncan

Trailing-12-Month Return on Equity



$110.3 million / $0


Salix Pharmaceuticals

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 69% of the 16 members who have rated Intercept believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, zzlangerhans, succinctly summed up the bear case for our community:

Intercept is now valued at [$580M]. That's not unheard of for a biopharma that recently went public in the midst of a phase III trial. ... I see vulnerability in the long time period before topline data is released in mid 2014. The major catalyst is the phase III trial of obeticholic acid (OCA) for primary biliary sclerosis. I believe the company is playing down the fact that they are developing OCA as a second-line therapy in PBS for patients who have failed treatment with the standard of care ursodiol. Also, the primary endpoint of the phase III trial is a composite of improvement in liver function tests. My understanding is that using LFT as an indicator of improvement or progression in PBS is controversial, and there is no SPA for the trial. Even with technically positive results of the trial, secondary endpoints may disappoint and the FDA may not be convinced.

I've been wrong about companies like this before and I may be completely misreading this situation. But my instinct tells me that Intercept is ripe for a pullback as traders move on to biopharmas with more near term catalysts, and on CAPS I go with my instincts.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2383341, ~/Articles/ArticleHandler.aspx, 9/30/2016 2:41:43 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,339.35 195.90 1.08%
S&P 500 2,173.05 21.92 1.02%
NASD 5,321.28 52.13 0.99%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 2:22 PM
ICPT $165.71 Up +5.48 +3.42%
Intercept Pharmace… CAPS Rating: **
AZN $32.98 Down -0.08 -0.23%
AstraZeneca CAPS Rating: ****
SLXP.DL $0.00 Down +0.00 +0.00%
Salix Pharmaceutic… CAPS Rating: ***